Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib

​Taletrectinib targets precocious ROS1-positive non-small compartment lung cancer. Management noted that they expect a modular reappraisal timeline. This builds connected the earlier January 2026 exclusive licensing woody betwixt Eisai and Nuvation Bio for Europe and prime regions extracurricular the US, China, and Japan.

​Management noted that Europe sees astir 400,000 yearly lung crab diagnoses, retired of which non-small compartment lung crab comprises 80% of the cases and much than 2% precocious ROS1-positive cases. This translates to astir 6,400 patients a year. Taletrectinib is simply a highly selective oral ROS1 inhibitor with a beardown efficacy and information profile, positioning it arsenic a imaginable standard-of-care.

​Nuvation Bio Inc. (NYSE:NUVB) is simply a biopharmaceutical institution processing caller treatments for difficult-to-treat cancers. The institution was founded by David Hung successful 2018, and its office are successful New York City.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.